Houston, Texas and Tuebingen, Germany, October 4, 2024 – Immatics N.V. (NASDAQ: IMTX, "Immatics" or the "Company"), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced upcoming oral and poster presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer in Houston, Texas from November 6 - 10, 2024. Full abstracts will be available on November 5, 2024, at 9:00 am EST in the JITC Supplement. Ora ...

TCER® IMA401 is a novel, next-generation, half-life extended bispecific T cell engager directed against an HLA-A*02-presented peptide derived from MAGEA4 and MAGEA8 with high target copy numbers on various solid cancers Data from the first-in-human Phase 1 dose escalation trial demonstrate initial anti-tumor activity and a manageable tolerability profile for TCER® IMA401 monotherapy; patient population includes 35 heavily pre-treated patients across 16 different solid tumor types; dose escalation is ongoing ...

Core Insights - Immatics N.V. announced updated clinical data on its lead cell therapy candidate, ACTengine® IMA203, targeting PRAME, to be presented at the 21st International Congress of the Society for Melanoma Research [1] Group 1: Clinical Data Presentation - The oral presentation is scheduled for October 11, 2024, from 8:00 to 8:20 am Central Daylight Time, during the Plenary Session 1 focused on Developmental Immunotherapy [2] - The presentation will be delivered by Dr. Martin Wermke from University Hospital Dresden, Germany, and will provide a clinical update on ACTengine IMA203 TCR-T targeting PRAME in PD1-refractory metastatic melanoma [2] Group 2: About ACTengine IMA203 - ACTengine® IMA203 is an autologous T cell product with a genetically modified TCR directed against a peptide derived from PRAME, which is frequently expressed in various solid cancers [2] - The PRAME peptide is characterized by high copy numbers per tumor cell and is specifically expressed in tumor tissue, indicating its potential for a broad cancer patient population [2] - Immatics utilizes its proprietary mass spectrometry-based target discovery platform, XPRESIDENT®, and TCR discovery and engineering platform, XCEPTOR®, to develop this targeted therapy [2] Group 3: Current Trials - ACTengine® IMA203 is currently being evaluated in a Phase 1 trial as a monotherapy and as a second-generation IMA203CD8 (GEN2) monotherapy, which combines both CD4+ and CD8+ T cells [3] - The combination of IMA203 with an immune checkpoint inhibitor has been deprioritized in the development pipeline [3] Group 4: Company Overview - Immatics focuses on discovering true targets for cancer immunotherapies and developing specific T cell receptors to enable robust T cell responses against these targets [4] - The company aims to deliver the power of T cells and unlock new treatment avenues for cancer patients through its pipeline of Adoptive Cell Therapies and TCR Bispecifics [4]

Immatics (IMTX) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.35 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 48.57%. A quarter ago, it was expected that this company would post a loss of $0.74 per share when it actually produced a loss of $0.04, delivering a surprise of 94.59%. Over the last four quarters, the company has surpassed con ...

Exhibit 99.1 As used in this interim report, the terms "Immatics", "we", "our", "us", "the Group" and "the Company" refer to Immatics N.V. and its subsidiaries, taken as a whole, unless the context otherwise requires. The unaudited interim condensed consolidated financial statements and Management's Discussion & Analysis of Financial Condition and Results of Operations in this interim report are related to Immatics N.V. and its German subsidiary Immatics Biotechnologies GmbH as well as its U.S. subsidiary I ...

Core Insights - Immatics N.V. reported a confirmed objective response rate of 55% for its ACTengine® IMA203 targeting PRAME in a Phase 1 trial involving 30 heavily pre-treated metastatic melanoma patients, with a median duration of response of 13.5 months [1][4][5] - The company plans to initiate a registration-enabling randomized Phase 2/3 trial for ACTengine® IMA203 in 2024 and will present further data updates in the second half of 2024 [1][2][3] - Immatics has a strong cash position of €531.1 million ($568.5 million) as of June 30, 2024, which is expected to fund operations into 2027 [1][15] Clinical Development - The IMA203 monotherapy demonstrated a disease control rate of 90% and tumor shrinkage in 87% of patients [4][5] - The next data update for IMA203 and IMA203CD8 (GEN2) is scheduled for the second half of 2024, focusing on translational and clinical data [1][5][6] - Immatics is expanding its clinical focus beyond melanoma to include ovarian and uterine cancers [6] TCR Bispecific Programs - Immatics is developing next-generation T cell engaging receptor (TCER®) candidates, including IMA401 and IMA402, designed to enhance efficacy while minimizing toxicities [7][13] - Initial clinical data for TCER® IMA401 will be presented at the ESMO Congress on September 16, 2024 [8][9] - IMA402 is currently in a Phase 1/2 trial targeting PRAME and is focused on multiple solid tumors, including ovarian and lung cancers [13] Corporate Developments - Alise Reicin, M.D., was appointed to the Board of Directors, bringing extensive experience in clinical development [14] - The company reported total revenue of €18.8 million ($20.1 million) for Q2 2024, a decrease from €22.4 million ($24.0 million) in Q2 2023, primarily due to a one-time revenue in the previous year [16] - Research and development expenses increased to €35.2 million ($37.7 million) in Q2 2024, reflecting ongoing advancements in the clinical pipeline [17] Financial Performance - Immatics reported a net loss of €18.0 million ($19.3 million) for Q2 2024, an improvement from a net loss of €24.6 million ($26.3 million) in Q2 2023 [19] - The company’s cash position increased from €425.9 million ($455.9 million) at the end of 2023 to €531.1 million ($568.5 million) by June 30, 2024, mainly due to a public offering [15][16] - Total assets as of June 30, 2024, were €626.97 million, up from €509.97 million at the end of 2023 [26]

Core Insights - Immatics N.V. has appointed Dr. Alise Reicin to its Board of Directors, bringing extensive experience in the pharmaceutical industry and a history of developing significant therapies like Keytruda® [1][2][3] - Dr. Reicin's leadership is expected to enhance Immatics' efforts in advancing TCR-based therapies for solid tumors, addressing unmet medical needs in cancer treatment [2][8] Company Overview - Immatics is a clinical-stage biopharmaceutical company focused on discovering and developing T cell-redirecting cancer immunotherapies, with a pipeline that includes Adoptive Cell Therapies and TCR Bispecifics [4] - The company aims to enable robust T cell responses against cancer targets, leveraging partnerships with global pharmaceutical leaders [4] Leadership Experience - Dr. Reicin has held key positions in various pharmaceutical companies, including President of Global Clinical Development at Celgene and Senior Vice President at EMD Serono, contributing to the approval of multiple drugs [3] - Under her leadership at Tectonic Therapeutic, the company completed an $80 million Series A financing and advanced its first asset into clinical trials [3] Future Outlook - Dr. Reicin's appointment is set to continue through the Company's Annual General Meeting in 2025, indicating a long-term commitment to guiding Immatics' strategic direction [9] - The company is at a dynamic stage of development, particularly with its lead cell therapy candidate, ACTengine® IMA203, showing promising results in advanced metastatic melanoma patients [8]

The mean estimate comprises five short-term price targets with a standard deviation of $3.71. While the lowest estimate of $16 indicates a 27.8% increase from the current price level, the most optimistic analyst expects the stock to surge 99.7% to reach $25. It's very important to note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts. Price, Consensus and EPS Surprise While Wall Street analysts ...

Often, the direction of a stock's price movement reverses quickly after taking a position in it, making investors incur a short-term capital loss. So, it's important to ensure that there are enough factors -- such as sound fundamentals, positive earnings estimate revisions, etc. -- that could keep the momentum in the stock going. Immatics (IMTX) is one of the several suitable candidates that passed through the screen. Here are the key reasons why it could be a profitable bet for "trend" investors. However, ...

Full abstracts will be available on the ESMO website on Monday, September 9, 2024, at 00:05 CEST. Date / Time: September 16, 2024 / 11:25 CEST Session: Investigational Immunotherapy Title: Initial safety, pharmacokinetics, and anti-tumor activity data of TCER IMA401, a MAGEA4/8-directed half-life extended TCR Bispecific, in Phase 1 dose escalation Presenting author: Martin Wermke, MD (University Hospital Dresden, Germany) Room: Granada Auditorium - Hall 6 IMA401 is Immatics' most advanced TCER® molecule tha ...